Dr Sameer Greenall is a translational cancer Research Fellow at the Department of Oncology, Monash University and Monash Health. A lifelong Australian researcher, he completed his B.Sc (Hons) as an immunopathologist at the University of Melbourne in 2002 and completed his PhD at the University of Melbourne and CSIRO as a CSIRO postgraduate awardee in 2008, assembling and studying recombinant viral vaccines and antibody fragment technologies.
Dr Greenall has conducted his research into cancer therapy starting as the Ron Evans Cancer Research Fellow at the Monash Institute of Medical Research in Melbourne in 2008-2010, followed by Biosciences Division, CSIRO as an OCE Postdoctoral Fellow from 2011-2014 and finally at the Hudson Institute of Medical Research from 2014-2018. During this time, Dr Greenall has produced a stable of scientific works which cement his expertise and reputation as a cancer therapeutics specialist in the antibody and small molecule inhibitor fields. His primary focus on antibody targeting of a truncated autoactive receptor, EGFRvIII, which drives gliomagenesis in 30% of patients has resulted in the discovery of how this receptor self-assembles and autoactivates, how it transactivates other cell surface receptors and how some clinical antibodies which target this receptor can fail to neutralise its activity, resulting in resistance. His works also document new and undiscovered mechanisms of action of other antibodies against EGFRvIII as well as detailed biological interrogations of previously uncharacterised point mutations in the EGFR in glioblastoma and their propensity to drive cancer growth. Each of these has subsequently resulted in new combinations therapies being successfully preclinically tested for greater activity against glioblastoma. Recently, Dr Greenall has dramatically expanded the breadth of his research agenda, producing several studies describing the mechanism and efficacy of small molecule agents against new therapeutic targets to treat several subtypes of glioblastoma, such as CDK7 and OLIG2, as well as discovering that rilotumumab, a phase III antibody which has failed clinically, is unable to fully neutralise its cognate target, explaining
its lack of efficacy in trials.
Since May 2018, he is a translational Research Fellow in the Segelov laboratory applying his expertise to the exciting and ground-breaking immune checkpoint class of inhibitors in non-small cell lung carcinoma and glioblastoma. His interests currently lie in understanding why some lung cancer patients who are treated with immune checkpoint antibodies do not respond or respond but then progress. He is also analysing several new theories and approaches to improve immune checkpoint therapy for the better treatment of glioblastoma. His research has been published in several reputable international journals and has been presented both nationally and internationally.
He is an active member of the American Association for Cancer Research (AACR), The Society for Neuro-Oncology (SNO) and the Cooperative Trials Group for Neuro-Oncology (COGNO).